-
1
-
-
42949171158
-
-
American Cancer Society, Atlanta, GA. Accessed 19 Nov 2009
-
Garcia M, Jemal A, Ward EM, Center MM, Hao Y, Siegel RL, Thun MJ (2007) Global Cancer Facts & Figures 2007. American Cancer Society, Atlanta, GA. http://www.cancer.org/docroot/STT/STT-asp. Accessed 19 Nov 2009
-
(2007)
Global Cancer Facts & Figures 2007
-
-
Garcia, M.1
Jemal, A.2
Ward, E.M.3
Center, M.M.4
Hao, Y.5
Siegel, R.L.6
Thun, M.J.7
-
2
-
-
33747829208
-
-
American Cancer Society . Atlanta, GA: American Cancer Society. Accessed 19 Nov 2009
-
American Cancer Society (2009) Breast Cancer Facts & Figures 2009-2010. Atlanta, GA: American Cancer Society. http://www. cancer.org/docroot/STT/STT-0.asp. Accessed 19 Nov 2009
-
(2009)
Breast Cancer Facts & Figures
, pp. 2009-2010
-
-
-
3
-
-
18044372636
-
Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer
-
Pasqualini JR, Chetrite GS (2005) Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. J Steroid Biochem Mol Biol 93:221-236
-
(2005)
J Steroid Biochem Mol Biol
, vol.93
, pp. 221-236
-
-
Pasqualini, J.R.1
Chetrite, G.S.2
-
4
-
-
34548404274
-
New experimental models for aromatase inhibitor resistance
-
DOI 10.1016/j.jsbmb.2007.05.020, PII S0960076007001173, Proceedings of the VIII International Aromatase Conference 'Aromastase 2006' (Baltimore, Maryland USA, 18-20 September, 2006)
-
Chen S, Masri S, Hong YY, Wang X, Phung S, Yuan YC, Wu X (2007) New experimental models for aromatase inhibitor resistance. J Steroid Biochem Mol Biol 106:8-15. doi: 10.1016/j. jsbmb.2007.05.020 (Pubitemid 47362647)
-
(2007)
Journal of Steroid Biochemistry and Molecular Biology
, vol.106
, Issue.1-5
, pp. 8-15
-
-
Chen, S.1
Masri, S.2
Hong, Y.3
Wang, X.4
Phung, S.5
Yuan, Y.-C.6
Wu, X.7
-
5
-
-
61649124894
-
New developments in intracrinology of human breast cancer estrogen sulfatase and sulfotransferase
-
Sasano H, Nagasaki S, Miki Y, Suzuki T (2009) New developments in intracrinology of human breast cancer estrogen sulfatase and sulfotransferase. Ann NY Acad Sci 1155:76-79
-
(2009)
Ann NY Acad Sci
, vol.1155
, pp. 76-79
-
-
Sasano, H.1
Nagasaki, S.2
Miki, Y.3
Suzuki, T.4
-
6
-
-
0016264368
-
Oestradiol synthesis by a human breast carcinoma
-
Miller WR, Forrest AP (1974) Oestradiol synthesis by a human breast carcinoma. Lancet 2:866-868
-
(1974)
Lancet
, vol.2
, pp. 866-868
-
-
Miller, W.R.1
Forrest, A.P.2
-
7
-
-
0025151257
-
Regulation of estrogen concentrations in human breast tissues
-
DOI 10.1111/j.1749-6632.1990.tb34296.x
-
James VH, Reed MJ, Lai LC, Ghilchik MW, Tait GH, Newton CJ, Coldham NG (1990) Regulation of estrogen concentrations in human breast tissues. Ann NY Acad Sci 595:227-235 (Pubitemid 20282953)
-
(1990)
Annals of the New York Academy of Sciences
, vol.595
, pp. 227-235
-
-
James, V.H.T.1
Reed, M.J.2
Lai, L.C.3
Ghilchik, M.W.4
Tait, G.H.5
Newton, C.J.6
Coldham, N.G.7
-
8
-
-
0036069975
-
Local uptake and synthesis of oestrone in normal and malignant postmenopausal breast tissues
-
Larionov AA, Berstein LM, Miller WR (2002) Local uptake and synthesis of oestrone in normal and malignant postmenopausal breast tissues. J Steroid Biochem Mol Biol 81:57-64
-
(2002)
J Steroid Biochem Mol Biol
, vol.81
, pp. 57-64
-
-
Larionov, A.A.1
Berstein, L.M.2
Miller, W.R.3
-
9
-
-
0020326596
-
Significance of aromatase activity in human breast cancer
-
Miller WR, Hawkins RA, Forrest APM (1982) Significance of aromatase activity in human breast cancer. Cancer Res 42: S3365-S3368
-
(1982)
Cancer Res
, vol.42
-
-
Miller, W.R.1
Hawkins, R.A.2
Forrest, A.P.M.3
-
10
-
-
34248597727
-
Aromatase localization in human breast cancer tissues: Possible interactions between intratumoral stromal and parenchymal cells
-
DOI 10.1158/0008-5472.CAN-06-3105
-
Miki Y, Suzuki T, Tazawa C, Yamaguchi Y, Kitada K, Honma S, Moriya T, Hirakawa H, Evans DB, Hayashi S, Ohuchi N, Sasano H (2007) Aromatase localization in human breast cancer tissues: possible interactions between intratumoral stromal and parenchymal cells. Cancer Res 67:3945-3954 (Pubitemid 46762184)
-
(2007)
Cancer Research
, vol.67
, Issue.8
, pp. 3945-3954
-
-
Miki, Y.1
Suzuki, T.2
Tazawa, C.3
Yamaguchi, Y.4
Kitada, K.5
Honma, S.6
Moriya, T.7
Hirakawa, H.8
Evans, D.B.9
Hayashi, S.-I.10
Ohuchi, N.11
Sasano, H.12
-
11
-
-
0031712804
-
Intratumoral aromatase in human breast, endometrial, and ovarian malignancies
-
DOI 10.1210/er.19.5.593
-
Sasano H, Harada N (1998) Intratumoral aromatase in human breast, endometrial, and ovarian malignancies. Endocr Rev 19:593-607 (Pubitemid 28467713)
-
(1998)
Endocrine Reviews
, vol.19
, Issue.5
, pp. 593-607
-
-
Sasano, H.1
Harada, N.2
-
12
-
-
0022930325
-
Enzymatic control of estrogen production in human breast cancer: Relative significance of aromatase versus sulfatase pathways
-
Santen RJ, Leszczynski D, Tilson-Mallet N, Feil PD, Wright C, Manni A, Santner S (1986) Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulfatase pathways. Ann N Y Acad Sei 464:126-137 (Pubitemid 17197627)
-
(1986)
Annals of the New York Academy of Sciences
, vol.VOL. 464
, pp. 126-137
-
-
Santen, R.J.1
Leszczynski, D.2
Tilson-Mallet, N.3
-
13
-
-
0025684712
-
Relationship between tumour aromatase activity, tumour characteristics and response to therapy
-
Miller WR, Anderson TJ, Jack WJL (1990) Relationship between tumour aromatase activity, tumour characteristics and response to therapy. J Steroid Biochem Mol Biol 37:1055-1059
-
(1990)
J Steroid Biochem Mol Biol
, vol.37
, pp. 1055-1059
-
-
Miller, W.R.1
Anderson, T.J.2
Jack, W.J.L.3
-
14
-
-
0037939776
-
Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma
-
14. Suzuki T, Nakata T, Miki Y, Kaneko C, Moriya T, Ishida T, Akinaga S, Hirakawa H, Kimura M, Sasano H (2003) Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma. Cancer Res 63:2762-2770 (Pubitemid 36667146)
-
(2003)
Cancer Research
, vol.63
, Issue.11
, pp. 2762-2770
-
-
Suzuki, T.1
Nakata, T.2
Miki, Y.3
Kaneko, C.4
Moriya, T.5
Ishida, T.6
Akinaga, S.7
Hirakawa, H.8
Kimura, M.9
Sasano, H.10
-
16
-
-
0043239221
-
Inhibition of aromatase: Insights from recent studies
-
Santen RJ (2003) Inhibition of aromatase: insights from recent studies. Steroids 68:559-567
-
(2003)
Steroids
, vol.68
, pp. 559-567
-
-
Santen, R.J.1
-
17
-
-
23744497498
-
Aromatase inhibitors: Cellular and molecular effects
-
DOI 10.1016/j.jsbmb.2005.04.010, PII S0960076005001731
-
Miller WR, Anderson TJ, White S, Larionov A, Murray J, Evans D, Krause A, Dixon JM (2005) Aromatase inhibitors: cellular and molecular effects. J Steroid Biochem Mol Biol 95:83-89 (Pubitemid 41137297)
-
(2005)
Journal of Steroid Biochemistry and Molecular Biology
, vol.95
, Issue.1-5
, pp. 83-89
-
-
Miller, W.R.1
Anderson, T.J.2
White, S.3
Larionov, A.4
Murray, J.5
Evans, D.6
Krause, A.7
Dixon, J.M.8
-
18
-
-
43149106508
-
Aromatase inhibitors: From bench to bedside and back
-
Geisler J (2008) Aromatase inhibitors: from bench to bedside and back. Breast Cancer 15:17-26
-
(2008)
Breast Cancer
, vol.15
, pp. 17-26
-
-
Geisler, J.1
-
19
-
-
17144423592
-
Aromatase inhibition: Translation into a successful therapeutic approach
-
DOI 10.1158/1078-0432.CCR-04-2187
-
Geisler J, Lønning PE (2005) Aromatase inhibition: translation into a successful therapeutic approach. Clin Cancer Res 11:28092821 (Pubitemid 40525179)
-
(2005)
Clinical Cancer Research
, vol.11
, Issue.8
, pp. 2809-2821
-
-
Geisler, J.1
Lonning, P.E.2
-
20
-
-
49649111492
-
Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor
-
Masri S, Phung S, Wang X, Wu X, Yuan YC, Wagman L, Chen S (2008) Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor. Cancer Res 68:4910-4918
-
(2008)
Cancer Res
, vol.68
, pp. 4910-4918
-
-
Masri, S.1
Phung, S.2
Wang, X.3
Wu, X.4
Yuan, Y.C.5
Wagman, L.6
Chen, S.7
-
21
-
-
60349130840
-
Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation?
-
Lønning PE (2009) Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation? Eur J Cancer 45:527-535
-
(2009)
Eur J Cancer
, vol.45
, pp. 527-535
-
-
Lønning, P.E.1
-
22
-
-
27944468748
-
Adaptation of estrogen-regulated genes in long-term estradiol deprived MCF-7 breast cancer cells
-
DOI 10.1007/s10549-005-5776-4
-
Santen RJ, Lobenhofer EK, Afshari CA, Bao Y, Song RX (2005) Adaptation of estrogen-regulated genes in long-term estradiol deprived MCF-7 breast cancer cells. Breast Cancer Res Treat 94:213-223 (Pubitemid 41677626)
-
(2005)
Breast Cancer Research and Treatment
, vol.94
, Issue.3
, pp. 213-223
-
-
Santen, R.J.1
Lobenhofer, E.K.2
Afshari, C.A.3
Bao, Y.4
Song, R.X.5
-
23
-
-
77950362569
-
Aromatase resistance mechanisms in model system in vivo
-
doi:10.1016/j.jsbmb.2009.09.004
-
Brodie A, Macedo L, Sabnis G (2009) Aromatase resistance mechanisms in model system in vivo. J Steroid Biochem Mol Biol. doi:10.1016/j.jsbmb.2009.09. 004
-
(2009)
J Steroid Biochem Mol Biol.
-
-
Brodie, A.1
Macedo, L.2
Sabnis, G.3
-
24
-
-
70349952517
-
Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors
-
Flågeng MH, Moi LL H, Dixon JM, Geisler J, Lien EA, Miller WR, Lønning PE, Mellgren G (2009) Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors. Br J Cancer 101:1253-1260
-
(2009)
Br J Cancer
, vol.101
, pp. 1253-1260
-
-
Flågeng, M.H.1
Moi, L.L.H.2
Dixon, J.M.3
Geisler, J.4
Lien, E.A.5
Miller, W.R.6
Lønning, P.E.7
Mellgren, G.8
-
25
-
-
77950862588
-
Neoadjuvant exemestane for 24 weeks in postmenopausal women with hormone receptor positive stage II or IUa breast cancer (JFMC34-0601) [abstract 591]
-
Sato N, Masuda N, Saji S, Takei H, Yamamoto Y, Sasano H, Toi M (2009) Neoadjuvant exemestane for 24 weeks in postmenopausal women with hormone receptor positive stage II or IUa breast cancer (JFMC34-0601) [abstract 591]. J Clin Oncol 27:15S
-
(2009)
J Clin Oncol 27:15S
-
-
Sato, N.1
Masuda, N.2
Saji, S.3
Takei, H.4
Yamamoto, Y.5
Sasano, H.6
Toi, M.7
-
26
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors
-
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Glabbeke MV, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216 (Pubitemid 30099779)
-
(2000)
Journal of the National Cancer Institute
, vol.92
, Issue.3
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
Wanders, J.4
Kaplan, R.S.5
Rubinstein, L.6
Verweij, J.7
Van Glabbeke, M.8
Van Oosterom, A.T.9
Christian, M.C.10
Gwyther, S.G.11
-
27
-
-
33645735920
-
Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole
-
Miller WR, White S, Dixon JM, Murray J, Renshaw L, Anderson TJ (2006) Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole. Br J Cancer 94:1051-1056
-
(2006)
Br J Cancer
, vol.94
, pp. 1051-1056
-
-
Miller, W.R.1
White, S.2
Dixon, J.M.3
Murray, J.4
Renshaw, L.5
Anderson, T.J.6
-
28
-
-
0024369033
-
Ki67 immunostaining in primary breast cancer: Pathological and clinical associations
-
Bouzubar N, Walker KJ, Griffiths K, Ellis IO, Elston CW, Robertson JFR, Blarney RW, Nicholson RI (1989) Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer 59:943-947 (Pubitemid 19155714)
-
(1989)
British Journal of Cancer
, vol.59
, Issue.6
, pp. 943-947
-
-
Bouzubar, N.1
Walker, K.J.2
Griffiths, K.3
Ellis, I.O.4
Elston, C.W.5
Robertson, J.F.R.6
Blamey, R.W.7
Nicholson, R.I.8
-
29
-
-
0032896905
-
Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer
-
Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474-1481
-
(1999)
J Clin Oncol
, vol.17
, pp. 1474-1481
-
-
Harvey, J.M.1
Clark, G.M.2
Osborne, C.K.3
Allred, D.C.4
-
30
-
-
33847147313
-
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
-
DOI 10.1200/JCO.2006.09.2775
-
Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145 (Pubitemid 350003059)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.1
, pp. 118-145
-
-
Wolff, A.C.1
Hammond, M.E.H.2
Schwartz, J.N.3
Hagerty, K.L.4
Allred, D.C.5
Cote, R.J.6
Dowsett, M.7
Fitzgibbons, P.L.8
Hanna, W.M.9
Langer, A.10
McShane, L.M.11
Paik, S.12
Pegram, M.D.13
Perez, E.A.14
Press, M.F.15
Rhodes, A.16
Sturgeon, C.17
Taube, S.E.18
Tubbs, R.19
Vance, G.H.20
Wheeler, T.M.21
Hayes, D.F.22
more..
-
31
-
-
36549059551
-
Multicenter phase II trial of neoadjuvant exemestane for postmenopausal patients with hormone receptor-positive, operable breast cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03)
-
Takei H, Suemasu K, Inoue K, Saito T, Okubo K, Koh J, Sato K, Tsuda H, Kurosumi M, Tabei T (2008) Multicenter phase II trial of neoadjuvant exemestane for postmenopausal patients with hormone receptor-positive, operable breast cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03). Breast Cancer Res Treat 107:87-94
-
(2008)
Breast Cancer Res Treat
, vol.107
, pp. 87-94
-
-
Takei, H.1
Suemasu, K.2
Inoue, K.3
Saito, T.4
Okubo, K.5
Koh, J.6
Sato, K.7
Tsuda, H.8
Kurosumi, M.9
Tabei, T.10
-
32
-
-
52949128414
-
Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: A phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17)
-
Mlineritsch B, Tausch C, Singer C, Luschin-Ebengreuth G, Jakesz R, Ploner F, Stierer M, Melbinger E, Menzel C, Urbania A, Fridrik M, Steger G, Wohlmuth P, Gnant M, Greil R (2008) Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17). Breast Cancer Res Treat 112:203-213
-
(2008)
Breast Cancer Res Treat
, vol.112
, pp. 203-213
-
-
Mlineritsch, B.1
Tausch, C.2
Singer, C.3
Luschin-Ebengreuth, G.4
Jakesz, R.5
Ploner, F.6
Stierer, M.7
Melbinger, E.8
Menzel, C.9
Urbania, A.10
Fridrik, M.11
Steger, G.12
Wohlmuth, P.13
Gnant, M.14
Greil, R.15
-
33
-
-
71049159605
-
Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer
-
Yamashita H, Takahashi S, Ito Y, Yamashita T, Ando Y, Toyama T, Sugiura H, Yoshimoto N, Kobayashi S, Fujii Y, Iwase H (2009) Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer. Cancer Sci. 100:2028-2033
-
(2009)
Cancer Sci.
, vol.100
, pp. 2028-2033
-
-
Yamashita, H.1
Takahashi, S.2
Ito, Y.3
Yamashita, T.4
Ando, Y.5
Toyama, T.6
Sugiura, H.7
Yoshimoto, N.8
Kobayashi, S.9
Fujii, Y.10
Iwase, H.11
-
34
-
-
59649087115
-
Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: A phase II trial
-
Barnadas A, Gil M, Gonzalez S, Tusquets I, Munoz M, Arcusa A, Prieto L, Margeli-Vila M, Moreno A (2009) Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial. Br J Cancer 100: 442-449
-
(2009)
Br J Cancer
, vol.100
, pp. 442-449
-
-
Barnadas, A.1
Gil, M.2
Gonzalez, S.3
Tusquets, I.4
Munoz, M.5
Arcusa, A.6
Prieto, L.7
Margeli-Vila, M.8
Moreno, A.9
-
35
-
-
0345314101
-
Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen
-
DOI 10.1016/S0959-8049(02)00600-7, PII S0959804902006007
-
Miller WR, Dixon JM, Macfarlane L, Cameron D, Anderson TJ (2003) Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen. Eur J Cancer 39:462-468 (Pubitemid 36173690)
-
(2003)
European Journal of Cancer
, vol.39
, Issue.4
, pp. 462-468
-
-
Miller, W.R.1
Dixon, J.M.2
Macfarlane, L.3
Cameron, D.4
Anderson, T.J.5
-
36
-
-
20244374413
-
Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: Influence of hormonal status and HER-2 in breast cancer - A study from the IMPACT trialists
-
DOI 10.1200/JCO.2005.07.559
-
Dowsett M, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, Smith IE (2005) Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer-a study from the IMPACT trialists. J Clin Oncol 23:2477-2492 (Pubitemid 47050838)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.11
, pp. 2477-2492
-
-
Dowsett, M.1
Ebbs, S.R.2
Dixon, J.M.3
Skene, A.4
Griffith, C.5
Boeddinghaus, I.6
Salter, J.7
Detre, S.8
Hills, M.9
Ashley, S.10
Francis, S.11
Walsh, G.12
Smith, I.E.13
-
37
-
-
33846965616
-
Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer
-
Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A'Hern R, Salter J, Detre S, Hills M, Walsh G (2007) Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 99:167-170
-
(2007)
J Natl Cancer Inst
, vol.99
, pp. 167-170
-
-
Dowsett, M.1
Smith, I.E.2
Ebbs, S.R.3
Dixon, J.M.4
Skene, A.5
A'Hern, R.6
Salter, J.7
Detre, S.8
Hills, M.9
Walsh, G.10
-
39
-
-
0035884620
-
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- And/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial
-
Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Jänicke F, Miller WR, Evans DB, Dugan M, Brady C, QuebeFehling E, Borgs M. (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J CIi Oncol 19:3808-3816
-
(2001)
J CIi Oncol
, vol.19
, pp. 3808-3816
-
-
Ellis, M.J.1
Coop, A.2
Singh, B.3
Mauriac, L.4
Llombert-Cussac, A.5
Jänicke, F.6
Miller, W.R.7
Evans, D.B.8
Dugan, M.9
Brady, C.10
Quebefehling, E.11
Borgs, M.12
-
40
-
-
0034132569
-
17β-hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: A correlation to clinicopathological parameters
-
Suzuki T, Moriya T, Ariga N, Kaneko C, Kanazawa M, Sasano H (2000) 1 Jbeta-hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters. Br J Cancer 82:518-523 (Pubitemid 30085183)
-
(2000)
British Journal of Cancer
, vol.82
, Issue.3
, pp. 518-523
-
-
Suzuki, T.1
Moriya, T.2
Ariga, N.3
Kaneko, C.4
Kanazawa, M.5
Sasano, H.6
-
41
-
-
60249089307
-
Reductive 17β-hydroxysteroid dehydrogenases in the sulfatase pathway: Critical in the cell proliferation of breast cancer
-
Aka JA, Mazumdar M, Lin SX (2009) Reductive 17β-hydroxysteroid dehydrogenases in the sulfatase pathway: Critical in the cell proliferation of breast cancer. Mol Cell Endocrinol 301: 183-190
-
(2009)
Mol Cell Endocrinol
, vol.301
, pp. 183-190
-
-
Aka, J.A.1
Mazumdar, M.2
Lin, S.X.3
|